Sino Biopharmaceutical Ltd - ESG Rating & Company Profile powered by AI
The report of Sino Biopharmaceutical Ltd is assembled by All Street Sevva using advanced Cognitive Robots. This webpage includes a questions and answers section for Sino Biopharmaceutical Ltd. Other corporations in the rating peer group for Sino Biopharmaceutical Ltd are shown.
Sino Biopharmaceutical Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.2; made up of an environmental score of 6.0, social score of 7.0 and governance score of 5.7.
6.2
Medium ImpactEnvironmental
Social
Governance
![Detailed ESG Breakdown](/resource/detailed-esg.png?ts=1725478325797)
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
427 | Scancell Holdings PLC | 6.3 | High |
427 | Verastem Inc | 6.3 | High |
450 | Sino Biopharmaceutical Ltd | 6.2 | High |
450 | Cannasouth Ltd | 6.2 | High |
450 | CareDx International AB | 6.2 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
![Peer Companies Benchmark](/resource/peer-benchmark-2.png?ts=1725478325797)
Frequently Asked Questions
Does Sino Biopharmaceutical Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Sino Biopharmaceutical Ltd disclose current and historical energy intensity?
Does Sino Biopharmaceutical Ltd report the average age of the workforce?
Does Sino Biopharmaceutical Ltd reference operational or capital allocation in relation to climate change?
Does Sino Biopharmaceutical Ltd disclose its ethnicity pay gap?
Does Sino Biopharmaceutical Ltd disclose cybersecurity risks?
Does Sino Biopharmaceutical Ltd offer flexible work?
Does Sino Biopharmaceutical Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Sino Biopharmaceutical Ltd disclose the number of employees in R&D functions?
Does Sino Biopharmaceutical Ltd conduct supply chain audits?
Does Sino Biopharmaceutical Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Sino Biopharmaceutical Ltd conduct 360 degree staff reviews?
Does Sino Biopharmaceutical Ltd disclose the individual responsible for D&I?
Does Sino Biopharmaceutical Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Sino Biopharmaceutical Ltd disclose current and / or historical scope 2 emissions?
Does Sino Biopharmaceutical Ltd disclose water use targets?
Does Sino Biopharmaceutical Ltd have careers partnerships with academic institutions?
Did Sino Biopharmaceutical Ltd have a product recall in the last two years?
Does Sino Biopharmaceutical Ltd disclose incidents of discrimination?
Does Sino Biopharmaceutical Ltd allow for Work Councils/Collective Agreements to be formed?
Has Sino Biopharmaceutical Ltd issued a profit warning in the past 24 months?
Does Sino Biopharmaceutical Ltd disclose parental leave metrics?
Does Sino Biopharmaceutical Ltd disclose climate scenario or pathway analysis?
Does Sino Biopharmaceutical Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Sino Biopharmaceutical Ltd disclose the pay ratio of women to men?
Does Sino Biopharmaceutical Ltd support suppliers with sustainability related research and development?
Does Sino Biopharmaceutical Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Sino Biopharmaceutical Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Sino Biopharmaceutical Ltd involved in embryonic stem cell research?
Does Sino Biopharmaceutical Ltd disclose GHG and Air Emissions intensity?
Does Sino Biopharmaceutical Ltd disclose its waste policy?
Does Sino Biopharmaceutical Ltd report according to TCFD requirements?
Does Sino Biopharmaceutical Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Sino Biopharmaceutical Ltd disclose energy use targets?
Does Sino Biopharmaceutical Ltd disclose its Renewable Energy targets?
![Only Subscribers](/resource/reload.png)
Are emissions metrics verified by STBi?
![Only Subscribers](/resource/reload.png)
Does Sino Biopharmaceutical Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Sino Biopharmaceutical Ltd
These potential risks are based on the size, segment and geographies of the company.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.